# JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

> **NCT02251821** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 61 (actual)

## Conditions studied

- Primary Myelofibrosis
- Secondary Myelofibrosis

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Melphalan
- **DRUG:** Methotrexate
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Ruxolitinib
- **DRUG:** Tacrolimus
- **RADIATION:** Total-Body Irradiation
- **PROCEDURE:** Umbilical Cord Blood Transplantation

## Key facts

- **NCT ID:** NCT02251821
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-20
- **Primary completion:** 2022-12-28
- **Final completion:** 2026-01-22
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02251821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02251821, "JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02251821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*